Achieve Life Sciences (ACHV) Registration filing summary

Company overview and business model

• Late-stage clinical specialty pharmaceutical company focused on addressing nicotine dependence through cytisinicline development and commercialization.

• Targets both combustible cigarette and e-cigarette users, with a significant addressable market in the U.S. and globally.

• Mission centers on reducing preventable deaths caused by tobacco use.

Financial performance and metrics

• Closed a private placement on April 17, 2026, raising approximately $180 million in gross proceeds before fees and expenses.

• Potential to receive an additional $173.8 million in gross proceeds if all common warrants are exercised.

Use of proceeds and capital allocation

• Proceeds intended to fund a Phase 3 clinical trial for cytisinicline for e-cigarette cessation, commercialization efforts, and general corporate purposes.